The impact of molecularly targeted therapies upon the understanding of Leukemogenesis and the role of hematopoietic stem cell transplantation in acute Promyelocytic Leukemia

Current Stem Cell Research and Therapy

Volumn 5, Issue 4, 2010, Pages 372-378

  Nagai, Sumimasa ^a   Takahashi, Tsuyoshi ^a   Kurokawa, Mineo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic trioxide; Leukemia initiating cells; Pml rara; Targeted therapy; Transplantation

Indexed keywords

ARSENIC TRIOXIDE; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID;

APOPTOSIS; CELL DIFFERENTIATION; FUSION GENE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKEMOGENESIS; MYELOID PROGENITOR CELL; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTE; PROMYELOCYTIC LEUKEMIA; REVIEW; SALVAGE THERAPY;

ANIMALS; APOPTOSIS; ARSENICALS; CELL DIFFERENTIATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; GLUTAMATES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MYELOID PROGENITOR CELLS; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; OXIDES; PRODRUGS; TRANSCRIPTION FACTORS; TRETINOIN; TUMOR SUPPRESSOR PROTEINS;

EID: 78649990546     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488810793351695     Document Type: Review

References (77)

1. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111: 2505-15.
2. Grimwade D, Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002; 16: 1959-73.
3. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113: 1875-91.
4. Nasr R, Guillemin MC, Ferhi O, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 2008; 14: 1333-42.
5. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2002; 2: 705-13.
6. Lallemand-Breitenbach V, Zhu J, Kogan S, Chen Z, de The H. Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia. Nat Rev Cancer 2005; 5: 821-7.
7. Villa R, Pasini D, Gutierrez A, et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 2007; 11: 513-25.
8. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 6: 3893-903.
9. Petrie K, Zelent A. Marked for death. Nat Cell Biol 2008; 10: 507-9.
10. Tatham MH, Geoffroy MC, Shen L, et al. RNF4 is a poly-SUMOspecific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 2008; 10: 538-46.
11. Lallemand-Breitenbach V, Jeanne M, Benhenda S, et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 2008; 10: 547-55.
12. Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107: 2627-32.
13. Lo Coco F, Ammatuna E, Sanz MA. Current treatment of acute promyelocytic leukemia. Haematologica 2007; 92: 289-91.
14. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 5328-35.
15. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of alltrans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009; 106: 3342-7.
16. Au WY, Chim CS, Lie AK, Liang R, Kwong YL. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol 2002; 117: 130-2.
17. Zheng X, Seshire A, Rüster B, et al. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica 2007; 92: 323-31.
18. Kogan SC. Curing APL: differentiation or destruction? Cancer Cell 2009; 15: 7-8.
19. Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC, de The H. Therapy-induced PML/RARA Proteolysis and Acute Promyelocytic Leukemia Cure. Clin Cancer Res 2009; 15: 6321-6.
20. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7.
21. Perry RL, Sanchez PV, Sarry JE, et al. A robust xenotransplantation model for acute myeloid leukemia. Blood 2008 abstract 2939.
22. Grimwade D, Enver T. Acute promyelocytic leukemia: where does it stem from? Leukemia 2004; 18: 375-84.
23. Pollock JL, Westervelt P, Walter MJ, Lane AA, Ley TJ. Mouse models of acute promyelocytic leukemia. Curr Opin Hematol 2001; 8: 206-11.
24. Westervelt P, Ley TJ. Seed versus soil: the importance of the target cell for transgenic models of human leukemias. Blood 1999; 93: 2143-8.
25. Early E, Moore MA, Kakizuka A, et al. Transgenic expression of PML/RARalpha impairs myelopoiesis. Proc Natl Acad Sci USA 1996; 93: 7900-4.
26. Turhan AG, Lemoine FM, Debert C, et al. Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia. Blood 1995; 85: 2154-61.
27. Guibal FC, Alberich-Jorda M, Hirai H, et al. Identification of a myeloid committed progenitor as the cancer initiating cell in acute promyelocytic leukemia. Blood 2009; 114: 5415-25.
28. Wojiski S, Guibal FC, Kindler T, et al. PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors. Leukemia 2009; 23: 1462-71.
29. Licht JD. Acute promyelocytic leukemia--weapons of mass differentiation. N Engl J Med 2009; 360: 928-30.
30. Kelly LM, Kutok JL, Williams IR, et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 2002; 99: 8283-8.
31. Kogan SC, Brown DE, Shultz DB, et al. BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia. J Exp Med 2001; 193: 531-43.
32. Edwards RH, Wasik MA, Finan J, et al. Evidence for early hematopoietic progenitor cell involvement in acute promyelocytic leukemia. Am J Clin Pathol 1999; 112: 819-27.
33. Foley R, Soamboonsrup P, Carter RF, et al. CD34-positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/ hypogranular morphology, expression of CD2 and bcr3 isoform. Am J Hematol 2001; 67: 34-41.
34. Albano F, Mestice A, Pannunzio A, et al. The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes. Haematologica 2006; 91: 311-6.
35. Chapiro E, Delabesse E, Asnafi V, et al. Expression of T-lineageaffiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17). Blood 2006; 108: 3484-93.
36. Minucci S, Monestiroli S, Giavara S, et al. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 2002; 100: 2989-95.
37. Lane AA, Ley TJ. Neutrophil elastase cleaves PML-RARalpha and is important for the development of acute promyelocytic leukemia in mice. Cell 2003; 115: 305-18.
38. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192-200.
39. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999; 93: 4131-43.
40. Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-53.
41. Ades L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French- Belgian-Swiss and PETHEMA results. Blood 2008; 111: 1078-84.
42. Lengfelder E, Haferlach C, Saussele S, et al. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: longterm results of the German AMLCG. Leukemia 2009; 23: 2298-58.
43. Burnett AK, Hills RK, Grimwade D, et al. Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial. Blood (ASH Annual Meeting Abstracts) 2007; 110: 589.
44. Lo Coco F, Avvisati G, Vignetti M, et al. Front-Line Treatment of Acute Promyelocytic Leukemia with AIDA Induction Followed by Risk-Adapted Consolidation: Results of the AIDA-2000 Trial of the Italian GIMEMA Group. Blood (ASH Annual Meeting Abstracts) 2004; 104: 392.
45. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006; 107: 3469-73.
46. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009; 27: 504-10.
47. Avvisati G, Petti MC, Lo Coco F, et al. AIDA: The Italian Way of treating acute promyelocytic leukemia (APL), Final act. ASH Annual Meeting Abstracts. Blood (ASH Annual Meeting Abstracts) 2003; 102: [abstract 142a].
48. Asou N, Kishimoto Y, Kiyoi H, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 2007; 110: 59-66.
49. Kelaidi C, Chevret S, De Botton S, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol 2009; 27: 2668-76.
50. Nagai S, Nannya Y, Hangaishi A, Takahashi T, Kurokawa M. The race and dose of chemotherapy should be considered for optimizing maintenance therapy for acute promyelocytic leukemia. Leuk Res 2009; 33: 1427-9.
51. Nagai S, Takahashi T, Kurokawa M. Risk-adapted maintenance therapy for acute promyelocytic leukemia. J Clin Oncol 2010; 28: e21.
52. Kharfan-Dabaja MA, Abou Mourad YR, Fernandez HF, Pasquini MC, Santos ES. Hematopoietic cell transplantation in acute promyelocytic leukemia: a comprehensive review. Biol Blood Marrow Transplant 2007; 13: 997-1004.
53. Sanz MA, Labopin M, Gorin NC, et al. Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2007; 39: 461-9.
54. Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009; 27: 3650-8.
55. Nagai S, Takahashi T, Kurokawa M. How should we prevent hematologic relapse of acute promyelocytic leukemia? J Clin Oncol 2010; 28: e62.
56. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-60.
57. Douer D, Hu W, Giralt S, Lill M, DiPersio J. Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 2003; 8: 132-40.
58. Thirugnanam R, George B, Chendamarai E, et al. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant 2009; 15: 1479-84.
59. Shigeno K, Naito K, Sahara N, et al. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol 2005; 82: 224-9.
60. Carmosino I, Latagliata R, Avvisati G, et al. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. Haematologica 2004; 89: 615-7.
61. de Botton S, Fawaz A, Chevret S, et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 2005; 23: 120-6.
62. Kohno A, Morishita Y, Iida H, et al. Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group. Int J Hematol 2008; 87: 210-6.
63. Stolzel F, Wermke M, Rollig C, Thiede C, Platzbecker U, Bornhauser M. Mobilization of PML/RAR{alpha} negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pretreated with arsenic trioxide. Haematologica 2010; 95: 171-2.
64. Narimatsu H, Emi N, Kohno A, et al. High incidence of secondary failure of platelet recovery after autologous and syngeneic peripheral blood stem cell transplantation in acute promyelocytic leukemia. Bone Marrow Transplant 2007; 40: 773-8.
65. Leoni F, Gianfaldoni G, Annunziata M, et al. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation. Haematologica 2002; 87: 485-9.
66. Nagai S, Nannya Y, Arai S, Yoshiki Y, Takahashi T, Kurokawa M. Molecular or cytogenetic monitoring and preemptive therapy for central nervous system relapse of acute promyelocytic leukemia. Haematologica 2010; 95: 169-71.
67. Montesinos P, Diaz-Mediavilla J, Deben G, et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica 2009; 94: 1242-9.
68. de Botton S, Sanz MA, Chevret S, et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia 2006; 20: 35-41.
69. Nagai S, Takahashi T, Kurokawa M. Beneficial and Adverse Effects of Molecularly Targeted Therapies for Acute Promyelocytic Leukemia in Central Nervous System. CNS Neurol Disord Drug Targets 2009; 8: 387-92.
70. Ko BS, Tang JL, Chen YC, et al. Extramedullary relapse after alltrans retinoic acid treatment in acute promyelocytic leukemia--the occurrence of retinoic acid syndrome is a risk factor. Leukemia 1999; 13: 1406-8.
71. Breccia M, Carmosino I, Diverio D, et al. Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count. Br J Haematol 2003; 120: 266-70.
72. Ades L, Chevret S, Raffoux E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006; 24: 5703-10.
73. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood 2009; 114: 5126-35.
74. Kaspers G, Gibson B, Grimwade D, Pession A, Smith O, Testi AM. Central nervous system involvement in relapsed acute promyelocytic leukemia. Pediatr Blood Cancer 2009; 53: 235-6.
75. Gleissner B, Siehl J, Korfel A, Reinhardt R, Thiel E. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 2002; 58: 390-6.
76. de Haas V, Vet RJ, Verhagen OJ, Kroes W, van den Berg H, van der Schoot CE. Early detection of central nervous system relapse by polymerase chain reaction in children with B-precursor acute lymphoblastic leukemia. Ann Hematol 2002; 81: 59-61.
77. van Oostenbrugge RJ, Hopman AH, Arends JW, Ramaekers FC, Twijnstra A. Treatment of leptomeningeal metastases evaluated by interphase cytogenetics. J Clin Oncol 2000; 18: 2053-8.